New drug cocktail aims to tame advanced prostate cancer

NCT ID NCT07230106

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 20, 2026 · Updated 29 times

Summary

This study tests two experimental drugs (HS-20093 or SHR2554) taken with standard hormone therapy in men with metastatic prostate cancer. The goal is to see if these combinations can lower PSA levels and control the cancer. About 218 men aged 18 to 80 with advanced disease will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nanjing Drum Tower Hospital
RECRUITING

Nanjing, Jiangsu, 210009, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Tianjin Medical University Cancer Institute and Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300060, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

PROSTATE CANCER